Lehouritis et al., 2013 - Google Patents
Bacterial-directed enzyme prodrug therapyLehouritis et al., 2013
View PDF- Document ID
- 15069544889699513895
- Author
- Lehouritis P
- Springer C
- Tangney M
- Publication year
- Publication venue
- Journal of Controlled Release
External Links
Snippet
Current conventional treatments for cancer lack tumour selectivity resulting in the destruction of healthy tissue and severe adverse effects to the patient in addition to limiting the administration dose and efficacy. Hence, it is imperative that we seek alternative approaches …
- 239000000651 prodrug 0 title abstract description 122
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1077—Beam delivery systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lehouritis et al. | Bacterial-directed enzyme prodrug therapy | |
| Raj et al. | Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy | |
| Sharma et al. | Emerging trends in the novel drug delivery approaches for the treatment of lung cancer | |
| Brys et al. | Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy | |
| Markman et al. | Nanomedicine therapeutic approaches to overcome cancer drug resistance | |
| Argilés et al. | Are there any benefits of exercise training in cancer cachexia? | |
| Marcucci et al. | How to improve exposure of tumor cells to drugs—Promoter drugs increase tumor uptake and penetration of effector drugs | |
| WO2007084670A3 (en) | Specific therapy using integrin ligands for treating cancer | |
| WO2009010287A3 (en) | Specific therapy and medicament using integrin ligands for treating cancer | |
| WO2011146777A3 (en) | Device and method for providing a synergistic combination of phototherapy and a non-light energy modality to the brain | |
| Zhang et al. | New tricks of old drugs: Repurposing non-chemo drugs and dietary phytochemicals as adjuvants in anti-tumor therapies | |
| EP4124346A3 (en) | Compositions and methods for treating diseases | |
| SG10201903112WA (en) | Treatment of cancer using coenzyme q10 combination therapies | |
| PH12013501513A1 (en) | Nanoparticles loaded with chemotherapeutic antitumoral drug | |
| WO2011009020A3 (en) | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | |
| WO2016090024A3 (en) | Combination therapy for treatment of cancer | |
| HK1224179A1 (en) | Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses | |
| WO2014160216A3 (en) | Dual targeting anticancer agents | |
| Kumar et al. | Nanocarriers-mediated therapeutics as a promising approach for treatment and diagnosis of lung cancer | |
| WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
| Blakeley et al. | Chemotherapy with cytotoxic and cytostatic agents in brain cancer | |
| WO2014115859A3 (en) | Combination molecularly targeted drug for tumor therapy and prevention | |
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2007082742A8 (en) | Isolated organ perfusion combination therapy of cancer | |
| WO2010057596A3 (en) | New therapy and medicament using integrin ligands for treating cancer |